Ohno et al. reported that rikkunshito at a dose of 7.5 g/day suppressed the increase in oral intake and the decrease in acylated ghrelin due to cisplatin administration from the start of the combined administration of S-1 and cisplatin to patients with gastric cancer (39). Here, GHRL is linked to gastric cancer.